Publish 3-yr Metastasis study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 16 Jan 2024
- Due
- 31 Dec 2025
- Delivered
- 4 Sep 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Publish 3-yr Metastasis study”
What we found
Evidence strength B What the grades mean
Myriad published 3-year Metastasis study in The Lancet Oncology on September 4, 2025, within the 2025 deadline.
-
B Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
“Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad's molecular residual disease (MRD) test, Precise® MRD, in patients with oligometastatic clear-cell rena” ✓ confirmed on the page
-
B Myriad Genetics Newsroom
“Key study finding: ctDNA levels detected using Precise MRD were associated with patients' response to metastasis-directed radiation therapy. DOI: 10.1016/S1470-2045(25)00380-8” ✓ confirmed on the page
Checked 8 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Publish
- Deliverable
- 3-yr Metastasis study
- Target
- 3 years
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Myriad Genetics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-MYGN-003928 · Corrections policy